However, mutant-specific inhibitors have the inherent limitations of SNIs (i.e. pathway feedback re-activation and/or resistance via mutations in PTEN/AKT [17]) and furthermore allow for continued pathway activity via remaining wild-type-PI3Kα retained by tumour cells. This evidence concerns the gene AKT1 and neoplasm.